Tag: Biocon Biologics
Biocon Biologics secures US market entry date for Bmab 1200, a...
Biocon Biologics and Janssen have finalized the settlement agreement to dismiss the pending Inter Partes Review (IPR) for US 10961307 before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademarks Office
Biocon Biologics recognized as an Asia IP Elite for 2023, IPR...
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year’s list.
Kedar Upadhye appointed as new CFO of Biocon Biologics
Current CFO MB Chinappa to take on a Strategic Finance role at Biocon Group
Biocon Biologics announces positive CHMP opinion for its biosimilar to treat...
The CHMP positive opinion will be considered by the European Commission whose decision on the approval is expected by the end of September 2023
Biocon Biologics’ new mAbs facility receives EU GMP certification for bBevacizumab
This approval reflects Biocon Biologics’ compliance with the highest international regulatory standards and enables the company to continue addressing the needs of patients
Biocon Biologics wins ‘ABEA : Bioprocessing Excellence in South Asia’ Award
The company garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey
Shreehas Tambe appointed as MD & CEO of Biocon Biologics
Mr Tambe takes over from Dr Arun Chandavarkar, who will continue to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics